Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319790 | 0.83 | NPC1 (0.33) | ALDH1A1TSHRHTR2AHRH1TAAR1 | |
| SCHEMBL14399290 | 0.75 | HTR2A (0.44) | HTR2AHRH1TAAR1MAPTKDM4E | |
| SCHEMBL2155213 | 0.73 | TP53 (0.38) | ALDH1A1TSHRMAPTMEN1KMT2A | |
| SCHEMBL11576584 | 0.71 | TDP1 (0.38) | ALDH1A1TSHRTDP1KDM4EGLA | |
| SCHEMBL5572993 | 0.70 | TP53 (0.35) | ALDH1A1TSHRMEN1KMT2AGLA | |
| SCHEMBL27554191 | 0.70 | ALDH1A1 (0.39) | ALDH1A1HTR2AHRH1TDP1MAPT | |
| SCHEMBL9910590 | 0.69 | MEN1 (0.37) | ALDH1A1TSHRHTR2AHRH1TAAR1 | |
| SCHEMBL27769844 | 0.69 | LOXL2 (0.38) | HTR2AHRH1TAAR1 | |
| SCHEMBL4867131 | 0.69 | MAOB (0.31) | ALDH1A1TDP1MAPTHTT | |
| SCHEMBL4924726 | 0.68 | GAA (0.34) | ALDH1A1TSHRTAAR1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | ALDH1A1 1593/4885TSHR 3688/4885HTR2A 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.